The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas.

MLA

Cleverley, Tesia L., et al. “The Host-Directed Therapeutic Imatinib Mesylate Accelerates Immune Responses to Mycobacterium Marinum Infection and Limits Pathology Associated with Granulomas.” PLoS Pathogens, vol. 18, no. 5, May 2023, pp. 1–32. EBSCOhost, https://doi.org/10.1371/journal.ppat.1011387.

APA

Cleverley, T. L., Peddineni, S., Guarner, J., Cingolani, F., Garcia, P. K., Koehler, H., Mocarski, E. S., & Kalman, D. (2023). The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas. PLoS Pathogens, 18(5), 1–32. https://doi.org/10.1371/journal.ppat.1011387

Chicago

Cleverley, Tesia L., Siri Peddineni, Jeannette Guarner, Francesca Cingolani, Pamela K. Garcia, Heather Koehler, Edward S. Mocarski, and Daniel Kalman. 2023. “The Host-Directed Therapeutic Imatinib Mesylate Accelerates Immune Responses to Mycobacterium Marinum Infection and Limits Pathology Associated with Granulomas.” PLoS Pathogens 18 (5): 1–32. doi:10.1371/journal.ppat.1011387.